

## Nebraska Chronic Renal Disease Program Pharmacy Update – January 2023



The Nebraska Chronic Renal Disease Program (CRD) is a client assistance program that provides payment for pharmaceutical and dialysis services to eligible Nebraska residents diagnosed with End-Stage Renal Disease (ESRD). It does not cover the costs related to any other illness.

### **Reimbursable Drug Formulary**

The Program's Reimbursable Drug Formulary has been updated and will go into effect on February 1, 2023. Only drugs listed on the Formulary are reimbursable through the CRD Program. The new Formulary will be available on the Program's webpage: [dhhs.ne.gov/renal](https://dhhs.ne.gov/renal) after February 1, and is included with this fax.

This is a summary of the changes going into effect on February 1, 2023:

- Added to the list of covered drugs:
  - Azathioprine
  - Cyclosporine Modified – *Caps only*
  - Droxidopa
  - Mupirocin – *Topical cream only*
  - Mycophenolate Mofetil
  - Mycophenolic Acid
  - Tacrolimus

It's important to note that all medications must be prescribed to be reimbursed and that only the listed vitamins – *specifically formulated for renal patients* – will be reimbursed.

The Program reimburses for generic drugs, unless there is not a generic available. Drugs not available in generic form are clearly indicated on the Formulary in the "Reimbursable" column. At this time, since the reimbursement rate for Sevelamer Carbonate (generic) / Renvela (brand) is the same, the Program will reimburse for both; however, this will be assessed annually and may change in the future.

Contact the Program at any time with questions or to check a drug's reimbursement price. The drug NDC number and quantity prescribed are needed to check pricing.